Observed survival at day +100, CR by day +100, and survival at day +180 post-HSCT in the overall patient population
| . | Defibrotide treatment group (n = 102) . | Historical-control cohort (n = 32) . | Adjusted difference in rate* . | P . |
|---|---|---|---|---|
| Survival by day +100, (n) | 39 | 8 | — | — |
| Observed survival by day +100,* (%) | 38.2 | 25 | 23 | .0109 |
| 95.1% CI | 28.8-47.7 | 9.9-40.1 | 5.2-40.8 | — |
| CR by day +100,* (n) | 26 | 4 | — | — |
| CR by day +100 (%) | 25.5 | 12.5 | 19 | .0160 |
| 95.1% CI | 17-34 | 1-24 | 3.5-34.6 | — |
| Survival by day +180,† (n) | 33 | 8 | — | — |
| Observed survival by day +180 (%) | 32.4 | 25 | 16.4 | .0669 |
| 95.1% CI | 23.5-41.5 | 9.9-40.1 | −1.2-34.1 | — |
| . | Defibrotide treatment group (n = 102) . | Historical-control cohort (n = 32) . | Adjusted difference in rate* . | P . |
|---|---|---|---|---|
| Survival by day +100, (n) | 39 | 8 | — | — |
| Observed survival by day +100,* (%) | 38.2 | 25 | 23 | .0109 |
| 95.1% CI | 28.8-47.7 | 9.9-40.1 | 5.2-40.8 | — |
| CR by day +100,* (n) | 26 | 4 | — | — |
| CR by day +100 (%) | 25.5 | 12.5 | 19 | .0160 |
| 95.1% CI | 17-34 | 1-24 | 3.5-34.6 | — |
| Survival by day +180,† (n) | 33 | 8 | — | — |
| Observed survival by day +180 (%) | 32.4 | 25 | 16.4 | .0669 |
| 95.1% CI | 23.5-41.5 | 9.9-40.1 | −1.2-34.1 | — |